Journal September 16, 2026 6 min read

Tirzepatide: What It Is Studied Alongside

Tirzepatide is a dual GLP-1 and GIP receptor agonist. This page maps the research landscape: the compounds, devices, and clinical contexts it is studied alongside, from bariatric surgery to endometrial cancer.

peptides-pro Editorial

Tirzepatide (LY3298176) is a synthetic peptide and a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor families. It is studied as a single agent and in combination with a range of other interventions, devices, and standard-of-care regimens. The evidence block for this page does not provide sequence, formula, or molecular weight identifiers, so those are not reported here.

All work described below centres on the incretin receptor pathway — specifically co-activation of GIP and GLP-1 receptors — and the downstream effects on gastric emptying, insulin and glucagon secretion, and energy balance.

Research Studies

Tirzepatide and preoperative optimisation before one anastomosis gastric bypass

A clinical trial is comparing three preoperative strategies before one anastomosis gastric bypass (OAGB) for severe obesity: tirzepatide for 60 days, a ketogenic diet for 4 weeks, or standard care [1]. The primary outcome is weight loss one year after surgery. Secondary outcomes include safety, surgical outcomes, and improvement in obesity-related conditions such as diabetes, high blood pressure, and sleep apnea [1]. This is a study of tirzepatide as a preoperative adjunct, not as a standalone therapy.

Tirzepatide and levonorgestrel intrauterine device for endometrial hyperplasia and grade 1 endometrial cancer

A phase II trial is studying whether adding tirzepatide injections to a levonorgestrel intrauterine device (LNG-IUD) improves pathologic response — the absence of cancer cells in tissue samples after treatment — in women with endometrial atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) or grade 1 endometrial cancer who are overweight or obese [2]. The study notes that over half of endometrial cancer cases are thought to be attributable to being overweight or obese, and the risk relationship appears to be weight dependent [2]. The population is specifically women with AH/EIN or grade 1 endometrial cancer and elevated body weight.

Tirzepatide and levonorgestrel IUD for EIN and early-stage endometrial cancer

A separate single-arm study is evaluating the feasibility, safety, and preliminary efficacy of tirzepatide in combination with standard LNG-IUD therapy in patients with endometrial intraepithelial neoplasia (EIN) or grade 1 endometrioid endometrial carcinoma with co-existing obesity and metabolic risk factors [3]. Participants receive tirzepatide once weekly while continuing standard clinical management with an LNG-IUD. The primary objective is pathologic response at approximately 6 months; secondary objectives include changes in metabolic parameters [3]. Treatment decisions remain at the discretion of the treating physician [3].

Tirzepatide and real-world outcomes in South Asian adults

A multicentre, prospective, observational study is following 330 adults in Pakistan who are starting tirzepatide as part of routine clinical care across ten diabetes and endocrinology centres [4]. All participants have obesity, and they are grouped into three cohorts based on blood sugar status at the start: obesity without diabetes, prediabetes with obesity, and type 2 diabetes [4]. The study aims to address the lack of data on tirzepatide in South Asian populations, and none from Pakistan specifically [4]. This is an observational study of tirzepatide as used in practice, not a controlled trial of a combination.

Tirzepatide and central centrifugal cicatricial alopecia

A pilot clinical trial is investigating whether tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults [5]. The main questions are whether tirzepatide improves symptoms and signs of active CCCA, whether it changes the activity of genes in the scalp — especially genes related to scarring — and whether it promotes hair regrowth [5]. Participants inject tirzepatide once weekly for 12 months, attend clinic visits for scalp examinations and photographs, and have scalp biopsies at baseline and after 6 months [5]. This is an early-phase study in a dermatologic context.

Tirzepatide and postbariatric hypoglycemia after Roux-en-Y gastric bypass

A case series described 3 patients with postbariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass who were treated with tirzepatide [6]. All patients presented with symptomatic hypoglycemia characterised by episodes of diaphoresis, visual disturbances, confusion, and documented low blood glucose levels occurring postprandially [6]. Conventional management strategies, including dietary modifications, acarbose, and other pharmacotherapies, were either partially effective or limited by side effects [6]. The report describes initiation of tirzepatide in this small clinical series [6].

Tirzepatide and ileal pouch-anal anastomosis with chronic high bowel frequency

A clinical trial is testing whether tirzepatide (Zepbound) can decrease bowel frequency in patients with an ileal pouch-anal anastomosis (IPAA or pouch) better than standard-of-care anti-diarrheal therapy [7]. The main question is whether tirzepatide reduces bowel frequency better than standard of care in this population [7]. Participants visit the clinic 5 times, answer symptom questions daily, take the study product as instructed, and provide stool samples 4 times [7]. This is a study of tirzepatide in a surgical-anatomy context, not a metabolic one.

Tirzepatide and gastric emptying in type 1 diabetes with overweight or obesity

A study is examining how tirzepatide affects stomach emptying in participants with type 1 diabetes mellitus (T1DM) and overweight or obesity [8]. Participation lasts about 8 weeks, including screening and follow-up [8]. The focus is on gastric emptying as a physiological endpoint in a population that is not the typical type 2 diabetes cohort.

Tirzepatide and intensified conventional care in early uncontrolled type 2 diabetes

A reference-only report indicates that in adults with early uncontrolled type 2 diabetes, tirzepatide compared with intensified conventional care reduced HbA1c levels and weight at 2 years [10]. This finding is reported as a fact from that source; it is not a study of a combination product but of tirzepatide against an active comparator regimen.

Tirzepatide and weight regain after discontinuation

A reference-only Bayesian longitudinal meta-analysis reconstructed aggregate data to estimate post-discontinuation weight-regain trajectories after semaglutide or tirzepatide [11]. The analysis notes that both agents produce substantial weight loss during treatment, but the trajectory of weight regain after discontinuation remains uncertain [11]. This work is about the off-treatment phase, not about stacking or co-administration.

Tirzepatide and cardiovascular event comparisons

A reference-only comment discusses a comparative effectiveness analysis of tirzepatide versus dulaglutide or semaglutide on major cardiovascular events in type 2 diabetes and cardiovascular disease, using two target-trial emulations [12]. This is a comparative study of tirzepatide against other incretin-based agents, not a combination study.

Tirzepatide and oral health implications

A reference-only article raises emerging oral health implications for oral medicine practice in the context of tirzepatide [9]. The evidence block does not provide further detail on the findings, so no specific claims are made here beyond the existence of that report.

What the evidence does not show

None of the studies in this evidence block describe tirzepatide stacked with another research compound in a controlled laboratory setting. The combinations studied are with medical devices (LNG-IUD), surgical procedures (OAGB, Roux-en-Y gastric bypass, IPAA), dietary interventions (ketogenic diet), or standard-of-care anti-diarrheal therapy. Where the evidence is a case series or a reference-only report, that is stated. No animal-only or in vitro data appear in this evidence block; all cited work is in human populations or is a meta-analysis of human data.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.